Bekaii-Saab, T. S., Melisi, D., Wilmink, H., Garufi, C., Tran, N., Tortora, G., Braud, F. D., Frodin, J., Lonardi, S., Lin, E., Babiker, H., Lin, B., Fornaro, L., Martín, A. M., Bridgewater, J., Knox, J. J., Vos-Geelen, J. D., Scott-Brown, M., Veronese, L., Ioannidis, S., Gilmartin, A., Janik, J. E., Guo, Y., Furuse, J., Ioka, T., Rimassa, L., Vogel, A. (2026). Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor–2 Rearrangement: Results From the Phase III FIGHT-302 Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco-26-00788